PMC6196891_01
Hemoglobin concentration before and after Sirolimus therapy.
CRIPE2018-7654278.001.jpg
PMC6196891_01_CRIPE2018-7654278.001.jpg
fig1
Within 2 months of initiating sirolimus therapy, she experienced cessation of hematochezia and melena, and her hemoglobin has since remained above 11 g/dl (Figure 1).